The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy

European Journal of Cancer

Volumn 51, Issue 5, 2015, Pages 610-619

  Thurner, Eva Maria ^a   Krenn Pilko, Sabine ^a   Langsenlehner, Uwe ^b   Stojakovic, Tatjana ^a   Pichler, Martin ^c   Gerger, Armin ^a   Kapp, Karin S ^a   Langsenlehner, Tanja ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Division of Internal Medicine   (Austria)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

C reactive protein; Inflammation; Prognosis; Prostate cancer; Radiotherapy

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; UNIVARIATE ANALYSIS; ADVERSE EFFECTS; AREA UNDER THE CURVE; BLOOD; DISEASE COURSE; METABOLISM; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME; UPREGULATION;

AGED; AREA UNDER CURVE; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84924561401     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.01.002     Document Type: Article

References (49)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. P.H. Gann Risk factors for prostate cancer Rev Urol 4 Suppl. 5 2002 s3 s10
3. J. Braeckman, and D. Michielsen Prognostic factors in prostate cancer Recent results Cancer Res 175 2007 25 32
4. J. Parsonnet, G.D. Friedman, D.P. Vandersteen, Y. Chang, J.H. Vogelman, N. Orentreich, et al. Helicobacter pylori infection and the risk of gastric carcinoma N Eng J Med 325 1991 1127 1131
5. J.M. Rhodes, and B.J. Campbell Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared Trends Mol Med 8 2002 10 16
6. J.C. Imperial Natural history of chronic hepatitis B and C J Gastroenerol Hepatol 14 Suppl. 1999 S1 S5
7. S. Lee, J.W. Choe, H.K. Kim, and J. Sung High-sensitivity C-reactive protein and cancer J Epidemiol 21 2011 161 168
8. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 2001 539 545
9. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
10. M. Hara, Y. Matsuzaki, T. Shimuzu, M. Tomita, T. Ayabe, Y. Enomoto, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer Anticancer Res 27 2007 3001 3004
11. M. Groblewska, B. Mroczko, U. Wereszczynska-Siemiatkowska, B. Kedra, M. Lukaszewicz, A. Baniukiewicz, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients Clin Chem Lab Med 46 2008 1423 1428
12. D.M. Steel, and A.S. Whitehead Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PRF/5 Biochem J 277 Pt 2 1991 477 482
13. B. Weinhold, A. Bader, V. Poli, and U. Ruther Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo Biochem J 325 Pt 3 1997 617 621
14. L. Marnell, C. Mold, and T.W. Du Clos C-reactive protein: ligands, receptors and role in inflammation Clin Immunol 117 2005 104 111
15. L.A. Hefler, N. Concin, G. Hofstetter, C. Marth, A. Mustea, J. Sehouli, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer Clin Cancer Res 14 2008 710 714
16. M. Schmid, A. Schneitter, S. Hinterberger, J. Seeber, A. Reinthaller, and L. Hefler Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer Obstet Gynecol 110 2007 1231 1236
17. S. Polterauer, C. Grimm, C. Tempfer, G. Sliutz, P. Speiser, A. Reinthaller, et al. C-reactive protein is a prognostic parameter in patients with cervical cancer Gynecol Oncol 107 2007 114 117
18. K. Hashimoto, Y. Ikeda, D. Korenaga, K. Tanoue, M. Hamatake, K. Kawasaki, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma Cancer 103 2005 1856 1864
19. J.E. Crozier, R.F. McKee, C.S. McArdle, W.J. Angerson, J.H. Anderson, P.G. Horgan, et al. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer Br J Surg 94 2007 1028 1032
20. B. Gagnon, M. Abrahamowicz, Y. Xiao, M.E. Beauchamp, N. MacDonald, G. Kasymjanova, et al. Small D. Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer Br J Cancer 102 2010 1113 1122
21. J. Szkandera, A. Gerger, B. Liegl-Atzwanger, G. Absenger, M. Stotz, H. Samonigg, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients Br J Cancer 109 2013 2316 2322
22. M. Tatokoro, K. Saito, Y. Iimura, Y. Fujii, S. Kawakami, and K. Kihara Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy J Urol 180 2008 515 519
23. J. Ishioka, K. Saito, M. Sakura, M. Yokoyama, Y. Matsuoka, N. Numao, et al. Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis Br J Cancer 107 2012 1031 1036
24. T.M. Beer, A.S. Lalani, S. Lee, M. Mori, K.M. Eilers, J.G. Curd, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial Cancer 112 2008 2377 2383
25. M. Ito, K. Saito, Y. Yasuda, G. Sukegawa, Y. Kubo, N. Numao, et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel Urology 78 2011 1131 1135
26. P.A. McArdle, K. Mir, A.S. Almushatat, A.M. Wallace, M.A. Underwood, and D.C. McMillan Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer Urol Int 77 2006 127 129
27. R.C. Prins, B.L. Rademacher, S. Mongoue-Tchokote, J.J. Alumkal, J.N. Graff, K.M. Eilers, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results Urol Oncol 30 2012 33 37
28. W.A. Hall, D.C. Nickleach, V.A. Master, R.S. Prabhu, P.J. Rossi, K. Godette, et al. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate Cancer 119 2013 3272 3279
29. P.A. McArdle, T. Qayyum, and D.C. McMillan Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up Urol Int 85 2010 482
30. Z.Q. Liu, L. Chu, J.M. Fang, X. Zhang, H.X. Zhao, Y.J. Chen, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis Asian J Androl 16 2014 467 471
31. J. Mohler, R.R. Bahnson, B. Boston, J.E. Busby, A. D'Amico, J.A. Eastham, et al. NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Cancer Network 8 2010 162 200
32. M.J. Proctor, D.C. McMillan, D.S. Morrison, C.D. Fletcher, P.G. Horgan, and S.J. Clarke A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer Br J Cancer 107 2012 695 699
33. H. Kuper, H.O. Adami, and D. Trichopoulos Infections as a major preventable cause of human cancer J Intern Med 248 2000 171 183
34. L.M. Wahl, and H.K. Kleinman Tumor-associated macrophages as targets for cancer therapy J Natl Cancer Inst 90 1998 1583 1584
35. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
36. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
37. B.R. Achyut, D.A. Bader, A.I. Robles, D. Wangsa, C.C. Harris, T. Ried, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling PLoS Genet 9 2013 e1003251
38. M.M. Green, C.T. Hiley, J.H. Shanks, I.C. Bottomley, C.M. West, R.A. Cowan, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome Int J Radiat Oncol Biol Phys 67 2007 84 90
39. S.F. Shariat, V.A. Anwuri, D.J. Lamb, N.V. Shah, T.M. Wheeler, and K.M. Slawin Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy J Clin Oncol 22 2004 1655 1663
40. J. Yang, M. Wezeman, X. Zhang, P. Lin, M. Wang, J. Qian, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis Cancer Cell 12 2007 252 265
41. B. Verhoven, Y. Yan, M. Ritter, L.Y. Khor, E. Hammond, C. Jones, et al. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08 Int J Radiat Oncol Biol Phys 86 2013 317 323
42. S. Kudahetti, G. Fisher, L. Ambroisine, C. Foster, V. Reuter, J. Eastham, et al. P53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer BJU Int 104 2009 20 24
43. R. Vergis, C.M. Corbishley, K. Thomas, A. Horwich, R. Huddart, V. Khoo, et al. Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation Int J Radiat Oncol Biol Phys 78 2010 35 41
44. N. Eiró, S. Bermudez-Fernandez, B. Fernandez-Garcia, S. Atienza, N. Beridze, S. Escaf, et al. Analysis of the expression of interleukins, interferon β, and nuclear factor-κ B in prostate cancer and their relationship with biochemical recurrence J Immunother 37 2014 366 373
45. M. Bolla, T.M. de Reijke, G. Van Tienhoven, A.C. Van den Bergh, J. Oddens, P.M. Poortmans, et al. Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
46. E.M. Horwitz, K. Bae, G.E. Hanks, A. Porter, D.J. Grignon, H.D. Brereton, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
47. L. Souhami, K. Bae, M. Pilepich, and H. Sandler Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31 J Clin Oncol 27 2009 2137 2143
48. S. Ziaran, F.M. Goncalves, and J. Breza Sr. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control World J Urol 31 2013 289 292
49. P. Luthra, P.M. Fall, and D. Dauser The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer Aging Male 11 2008 71 75